Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 ...( ROCKVILLE Md. Aug. 22 /- Novavax ...),Health

ROCKVILLE, Md., Aug. 22 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today the oral presentation of a paper entitled "Recombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses" at the AIDS Vaccine 07 conference in Seattle by Dr. Weimin Liu, University of Alabama School of Medicine at Birmingham (UAB). Dr. Liu presented results of pre-clinical immunological studies of improved HIV-1 virus-like particle (VLP) vaccines being developed by scientists at Novavax and leading vaccine experts at UAB, Emory University School of Medicine and Duke University School of Medicine with funding from the National Institutes of Health.

Commenting on the presentation, Dr. Rahul Singhvi, president and CEO of Novavax said, "The data presented today demonstrate that immunization with VLPs containing a consensus envelope protein is a promising approach to achieving the desired broadly neutralizing antibody response against the HIV-1 virus. These data also substantiate the promise of our recombinant VLP technology to design vaccines to ultimately generate an immune response that can prevent complex diseases such as HIV/AIDS."

Virus-like particles (VLPs) represent an attractive HIV-1 vaccine platform for a safe and effective vaccine against HIV/AIDS. VLPs have the potential to mimic the three-dimensional structure of a virus without the risk of replication or infection. Applications of the VLP technology have been limited in the past due to very low level incorporation of HIV-1 envelope glycoprotein, the principal target for neutralizing antibody responses, into the HIV-1 virus or recombinant VLPs. Scientists from Emory University and UAB, working closely with Novav
'/>"/>